CELEBREX
Drug
PFIZER INC.
Total Payments
$3.6M
Transactions
1,072
Doctors
114
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $6,000 | 1 | 0 |
| 2020 | $9,316 | 29 | 25 |
| 2019 | $407,265 | 32 | 29 |
| 2018 | $818,493 | 115 | 55 |
| 2017 | $2.3M | 895 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.2M | 894 | 91.2% |
| Consulting Fee | $285,073 | 32 | 8.0% |
| Travel and Lodging | $12,054 | 37 | 0.3% |
| Honoraria | $9,040 | 8 | 0.3% |
| Food and Beverage | $4,708 | 101 | 0.1% |
Payments by Type
Research
$3.2M
894 transactions
General
$310,875
178 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN | PFIZER INC. | $2.0M | 0 |
| PRECISION TRIAL BIOMARKER SUBSTUDY | PFIZER INC. | $485,303 | 0 |
| PEGASUSPROJ2A3191172663 A3191172 MIG PO CLEVELAND CLINIC | PFIZER INTERNATIONAL LLC | $249,500 | 0 |
| A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN | PFIZER INTERNATIONAL LLC | $60,000 | 0 |
| CELEBREX FOR PAIN MANAGEMENT AFTER TONSILLECTOMY | PFIZER INC. | $46,748 | 0 |
| PROVIDE MEDICAL OR SCIENTIFIC CONSULTING SERVICES RELATING TO PRECISION TRIAL FDA ADVISORY COMMITTEE MEETING | PFIZER INC. | $20,610 | 0 |
| WI208749 CELEBREX FOR PAIN MANAGEMENT AFTER TONSILLECTOMY | UPJOHN US 1 LLC | $6,000 | 0 |
Top Doctors Receiving Payments for CELEBREX — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Family Medicine | Leesburg, FL | $15.30 | 1 |
| , MD | Orthopaedic Surgery | Hackettstown, NJ | $14.96 | 1 |
| , MD | Orthopaedic Surgery | Hackettstown, NJ | $14.96 | 1 |
| , MD | Orthopaedic Surgery | Hackettstown, NJ | $14.96 | 1 |
| , MD | Rheumatology | Kansas City, MO | $14.61 | 1 |
| , M.D | Internal Medicine | Elgin, IL | $14.37 | 1 |
| , MD | Orthopaedic Surgery | Rolla, MO | $14.15 | 1 |
| , MD | Internal Medicine | Bel Air, MD | $13.77 | 1 |
| , M.D | Family Medicine | Merrillville, IN | $13.43 | 1 |
| , DO | Family Medicine | Crown Point, IN | $13.25 | 1 |
| , DO | Family Medicine | Valparaiso, IN | $13.25 | 1 |
| , M.D | Family Medicine | Crown Point, IN | $13.25 | 1 |
| , M.D | Cardiovascular Disease | Torrance, CA | $13.22 | 1 |
| , M.D | Interventional Cardiology | Torrance, CA | $13.22 | 1 |
| , M.D | Interventional Cardiology | Torrance, CA | $13.22 | 1 |
| , M.D | Cardiovascular Disease | Torrance, CA | $13.22 | 1 |
| , D.O | Pain Medicine | Dover, OH | $12.87 | 1 |
| , DO | Pain Medicine | Puyallup, WA | $12.70 | 1 |
| , MD | Family Medicine | Johnson City, TN | $12.45 | 1 |
| , MD | Emergency Medicine | Tyler, TX | $12.37 | 1 |
| , MD | Family Medicine | Bridgeport, MI | $12.08 | 1 |
| , MD | Family Medicine | Bridgeport, MI | $12.08 | 1 |
| , M.D | Internal Medicine | Oak Park, MI | $11.91 | 1 |
| , MD | Family Medicine | Zanesville, OH | $11.84 | 1 |
| , M.D | Family Medicine | Dixon, IL | $11.63 | 1 |
Ad
Manufacturing Companies
- PFIZER INC. $3.2M
- PFIZER INTERNATIONAL LLC $366,169
- UPJOHN US 1 LLC $6,000
- Pfizer Inc. $2,520
Product Information
- Type Drug
- Total Payments $3.6M
- Total Doctors 114
- Transactions 1,072
About CELEBREX
CELEBREX is a drug associated with $3.6M in payments to 114 healthcare providers, recorded across 1,072 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2021. In 2021, $6,000 was paid across 1 transactions to 0 doctors.
The most common payment nature for CELEBREX is "Unspecified" ($3.2M, 91.2% of total).
CELEBREX is associated with 7 research studies, including "A RANDOMIZED DOUBLE BLIND PARALLELGROUP STUDY OF CARDIOVASCULAR SAFETY IN OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS PATIENTS WITH OR AT HIGH RISK FOR CARDIOVASCULAR DISEASE COMPARING CELECOXIB WITH NAPROXEN AND IBUPROFEN" ($2.0M).